Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tracks pregnancy risks for NMOSD patients on UPLIZNA

NCT ID NCT05909761

Recruiting now Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Nov 16, 2025 · Last updated May 20, 2026 · Updated 23 times

Summary

This study follows 60 women with NMOSD who received UPLIZNA during pregnancy or within 6 months before getting pregnant. Researchers will collect information on pregnancy outcomes, such as birth defects, preterm birth, and low birth weight. The goal is to better understand the safety of UPLIZNA during pregnancy. No new treatments are given; participants follow their usual care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Colorado Denver

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.